CI-988

CI-988
Identifiers
CAS Number 130332-27-3
PubChem (CID) 108186
ChEMBL CHEMBL2062154
Chemical and physical data
Formula C35H42N4O6
Molar mass 614.73 g/mol
  (verify)

CI-988 (PD-134,308) is a drug which acts as a cholecystokinin antagonist, selective for the CCKB subtype. In animal studies it showed anxiolytic effects[1][2] and potentiated the analgesic action of both morphine[3] and endogenous opioid peptides,[4][5] as well as preventing the development of tolerance to opioids[6][7] and reducing symptoms of withdrawal.[8][9] Consequently, it was hoped that it might have clinical applications for the treatment of pain and anxiety in humans, but trial results were disappointing with only minimal therapeutic effects observed even at high doses.[10][11][12][13] The reason for the failure of CI-988 and other CCKB antagonists in humans despite their apparent promise in pre-clinical animal studies is unclear, although poor pharmacokinetic properties of the currently available drugs are a possible explanation,[14] and CCKB antagonists are still being researched for possible uses as adjuvants to boost the activity of other drugs.[15]

References

  1. ↑ Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proceedings of the National Academy of Sciences USA. 1990 Sep;87(17):6728-32. PMID 1975695
  2. ↑ Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. British Journal of Pharmacology. 1991 Sep;104(1):239-45. PMID 1686205
  3. ↑ Wiesenfeld-Hallin Z, Xu XJ, Hughes J, Horwell DC, Hökfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proceedings of the National Academy of Sciences USA. 1990 Sep;87(18):7105-9. PMID 1698290
  4. ↑ Durieux C, Derrien M, Maldonado R, Valverde O, Blommaert A, Fournié-Zaluski MC, Roques BP. CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration. Annals of the New York Academy of Sciences. 1994 Mar 23;713:355-7. PMID 8185186
  5. ↑ Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. Journal of Pharmacology and Experimental Therapeutics. 1994 Jul;270(1):77-88. PMID 8035345
  6. ↑ Xu XJ, Wiesenfeld-Hallin Z, Hughes J, Horwell DC, Hökfelt T. CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat. British Journal of Pharmacology. 1992 Mar;105(3):591-6. PMID 1628146
  7. ↑ Hoffmann O, Wiesenfeld-Hallin Z. The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats. Neuroreport. 1994 Dec 20;5(18):2565-8. PMID 7696605
  8. ↑ Maldonado R, Valverde O, Ducos B, Blommaert AG, Fournie-Zaluski MC, Roques BP. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308. British Journal of Pharmacology. 1995 Mar;114(5):1031-9. PMID 7780637
  9. ↑ Valverde O, Roques BP. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Neuroscience Letters. 1998 Mar 6;244(1):37-40. PMID 9578139
  10. ↑ Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biological Psychiatry. 1995 Dec 1;38(11):742-6. PMID 8580227
  11. ↑ Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology. 1995 Dec;15(6):428-34. PMID 8748432
  12. ↑ van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berlin). 1997 Feb;129(3):243-8. PMID 9084062
  13. ↑ Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, Price LH. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Research. 1999 Mar 22;85(3):225-40. PMID 10333376
  14. ↑ Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biological Psychiatry. 1999 Sep 15;46(6):860-2. PMID 10494457
  15. ↑ Le Guen S, Mas Nieto M, Canestrelli C, Chen H, Fournié-Zaluski MC, Cupo A, Maldonado R, Roques BP, Noble F. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone. Pain. 2003 Jul;104(1-2):139-48. doi:10.1016/S0304-3959(02)00486-4 PMID 12855323
This article is issued from Wikipedia - version of the 10/16/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.